What is the appropriate dosing and titration protocol for Giapreza (angiotensin II) in adults with septic shock?

Giapreza Dosing for Septic Shock

Start Giapreza at 20 ng/kg/min via continuous IV infusion, preferably through a central line, and titrate every 5 minutes by increments up to 15 ng/kg/min to achieve target MAP ≥65 mmHg, with a maximum of 80 ng/kg/min during the first 3 hours and a maintenance dose not exceeding 40 ng/kg/min. 1

Initial Dosing Protocol

Starting dose: 20 ng/kg/min IV infusion 1

Route of administration:

• Central venous line is recommended 1
• Must be diluted in 0.9% sodium chloride to achieve final concentration of 5,000 ng/mL or 10,000 ng/mL 1

Titration Strategy

Titration frequency: Every 5 minutes 1

Titration increments: Up to 15 ng/kg/min per adjustment 1

Dose limits:

• First 3 hours: Do not exceed 80 ng/kg/min 1
• Maintenance phase: Do not exceed 40 ng/kg/min 1
• Minimum dose: As low as 1.25 ng/kg/min may be used 1

Target: Mean arterial pressure (MAP) of 65 mmHg or higher 1

Clinical Context and Positioning

While the Surviving Sepsis Campaign guidelines establish norepinephrine as first-line vasopressor with vasopressin or epinephrine as second-line agents 2, Giapreza (angiotensin II) represents a non-catecholamine alternative for refractory shock. The guidelines do not specifically address angiotensin II as it was approved after their 2016 publication.

When to consider Giapreza: Real-world evidence suggests optimal timing is before norepinephrine-equivalent dose exceeds 0.2-0.3 µg/kg/min and before initiating a fourth-line vasopressor 3. Patients with norepinephrine-equivalent dose <0.2 µg/kg/min or those on ≤3 vasopressors demonstrated significantly greater catecholamine reduction compared to those above these thresholds 3.

Hemodynamic Response Timeline

Rapid onset of action:

• Median time to reach MAP ≥65 mmHg: 16 minutes (IQR 5-60 minutes) 3
• Significant MAP increase by hour 3: mean difference of 9.3 mmHg (95% CI 6.4-12.1) 3
• Significant norepinephrine-equivalent dose reduction by hour 3: mean difference 0.16 µg/kg/min (95% CI 0.10-0.22) 3

Down-Titration

Once underlying shock improves sufficiently:

• Down-titrate every 5-15 minutes 1
• Decrease by increments up to 15 ng/kg/min 1
• Base adjustments on blood pressure response 1

Preparation and Storage

Dilution requirements:

• Must dilute in 0.9% sodium chloride only 1
• Prepare to final concentration of 5,000 or 10,000 ng/mL 1

Storage:

• Room temperature (20-25°C): discard after 24 hours 1
• Refrigeration (2-8°C): discard after 24 hours 1
• Discard vial and unused portion after opening 1

Critical Safety Considerations

Thrombotic risk: The most common adverse reaction (>10% of patients) is thromboembolic events 1. Concurrent venous thromboembolism prophylaxis is mandatory 1.

Drug interactions:

• ACE inhibitors may increase response to Giapreza 1
• Angiotensin II receptor blockers (ARBs) may reduce response 1

Common Pitfalls to Avoid

1. Starting too late: Evidence suggests initiating before severe catecholamine requirements develop (NED >0.3 µg/kg/min) yields better catecholamine-sparing effects 3

2. Exceeding dose limits: Do not exceed 80 ng/kg/min in first 3 hours or 40 ng/kg/min for maintenance 1

3. Omitting VTE prophylaxis: Given thrombotic risk, this is non-negotiable 1

4. Peripheral administration: Central line access is recommended for optimal delivery 1

5. Improper dilution: Must use 0.9% sodium chloride only; other diluents are not validated 1

Monitoring Requirements

• Continuous blood pressure monitoring (arterial line preferred per sepsis guidelines) 2
• Titrate based on MAP response every 5 minutes initially 1
• Monitor for signs of thromboembolism 1
• Assess for clinical improvement in organ perfusion 1